AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33557762 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized protocol (IP) group - individualized rescue morphine dosing based on fentanyl test results (10 μg/kg if positive, 50 μg/kg if negative)
Number of subjects: 280
Study 33557762 — intervention group
Group type: COMPARATOR
Intervention: Conservative protocol (CP) group - fixed rescue morphine dosing (25 μg/kg)
Number of subjects: 280
Study 33557762 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized protocol (IP) group
Number of subjects: 280
Study 33119047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol), 2000 IU per day
Number of subjects: 25871
Study 33119047 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids, 1 g per day
Number of subjects: 25871
Study 33119047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for Vitamin D3)
Number of subjects: 25871
Study 33119047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for ω-3 fatty acids)
Number of subjects: 25871
Study 33119047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 25871
Study 33119047 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids
Number of subjects: 25871
Study 36028171 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Yag laser
Number of subjects: 50
Study 36028171 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 50
Study 36028171 — intervention group
Group type: EXPERIMENTAL
Intervention: RB (Rose Bengal)
Number of subjects: 50
Study 36028171 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclave
Number of subjects: 50
Study 36028171 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 50
Study 34461383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training associated with transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 24
Study 34461383 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training isolated
Number of subjects: 24
Study 616506959 — intervention group
Group type: EXPERIMENTAL
Intervention: Current NFP
Number of subjects: 213
Study 616506959 — intervention group
Group type: COMPARATOR
Intervention: Modified NFP (FDA proposals)
Number of subjects: 213
Study 616506959 — intervention group
Group type: EXPERIMENTAL
Intervention: Current NFP and modified NFP
Number of subjects: 213
Study 616506959 — intervention group
Group type: COMPARATOR
Intervention: Modified NFP formats
Number of subjects: 213
Study 35131155 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) (24/7)
Number of subjects: 114
Study 35131155 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (BGM) (4 times daily)
Number of subjects: 114
Study 34054830 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐26 levels in SLE patients
Number of subjects: 109
Study 34054830 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐26 levels in patients with active disease
Number of subjects: 109
Study 34054830 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL‐26 levels with SLEDAI score
Number of subjects: 109
Study 34054830 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL‐26 levels
Number of subjects: 109
Study 34054830 — intervention group
Group type: COMPARATOR
Intervention: IL‐26 performance compared to classical markers
Number of subjects: 109
Study 33035075 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric-resistance exercise program
Number of subjects: 15
Study 33035075 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15
Study 35258101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 2.5 mg (up-titrated to 5 mg and 10 mg) + nitroglycerin 0.4 mg sublingual
Number of subjects: 36
Study 35258101 — intervention group
Group type: COMPARATOR
Intervention: Placebo + nitroglycerin 0.4 mg sublingual
Number of subjects: 36
Study 35258101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat + nitroglycerin
Number of subjects: 36
Study 35258101 — intervention group
Group type: COMPARATOR
Intervention: Placebo + nitroglycerin
Number of subjects: 36
Study 33115353 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickDASH questionnaire
Number of subjects: 381
Study 33115353 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 70-79 and 80-89
Number of subjects: 381
Study 33115353 — intervention group
Group type: EXPERIMENTAL
Intervention: Females aged 50-59
Number of subjects: 381
Study 33115353 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion pain or tenderness at the shoulder and side pinch strength
Number of subjects: 381
Study 34385148 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME program (intervention)
Number of subjects: 55
Study 34385148 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW knowledge improvement
Number of subjects: 55
Study 33019392 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 50
Study 35377734 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison report via e-mail displaying individual hospice utilization metrics compared with top-performing peers
Number of subjects: 47
Study 35377734 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no report)
Number of subjects: 47
Study 35377734 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison report via e-mail
Number of subjects: 47
Study 34288357 — intervention group
Group type: EXPERIMENTAL
Intervention: 2NRTI + raltegravir
Number of subjects: 48
Study 34288357 — intervention group
Group type: COMPARATOR
Intervention: 2NRTI + EFV + losartan
Number of subjects: 48
Study 34288357 — intervention group
Group type: COMPARATOR
Intervention: 2NRTI + EFV
Number of subjects: 48
Study 34288357 — intervention group
Group type: COMPARATOR
Intervention: 2NRTI + raltegravir + losartan
Number of subjects: 48
Study 35780177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold plasma treatment combined with pyroligneous acid
Number of subjects: 0
Study 35780177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold plasma treatment
Number of subjects: 0
Study 35780177 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed plasma treatment combined with biochar application
Number of subjects: 0
Study 35780177 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding azolla compost
Number of subjects: 0
Study 35780177 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed plasma treatment with biochar
Number of subjects: 0
Study 35780177 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and azolla compost
Number of subjects: 0
Study 33516285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor 200 mg–ivacaftor 250 mg orally once every 12 h for up to 120 weeks
Number of subjects: 239
Study 33516285 — intervention group
Group type: COMPARATOR
Intervention: Lumacaftor–ivacaftor therapy
Number of subjects: 239
Study 35285923 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided ICBT
Number of subjects: 120
Study 35285923 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided ICBT
Number of subjects: 120
Study 35285923 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face CBT
Number of subjects: 120
Study 32134686 — intervention group
Group type: EXPERIMENTAL
Intervention: FHIR-based computational pipeline for electronic data capture (EDC)
Number of subjects: 287
Study 37563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-pigmentation scores (RPS)
Number of subjects: 0
Study 37563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitiligo noticeability scale (VNS)
Number of subjects: 0
Study 37563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitiligo specific quality of life instrument (VitiQoL)
Number of subjects: 0
Study 37563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Total VitiQoL score
Number of subjects: 0
Study 33539147 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative intervention
Number of subjects: 4
Study 33539147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Restorative and Compensatory intervention
Number of subjects: 4
Study 33539147 — intervention group
Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 4
Study 33238946 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers combined with mobile application on nutrition counselling
Number of subjects: 0
Study 33295267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation with destabilisation devices
Number of subjects: 26
Study 33295267 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation without destabilisation devices
Number of subjects: 26
Study 35109566 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCO health education program (8-week, 2-hours per week)
Number of subjects: 14
Study 35109566 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (received CoCO manual)
Number of subjects: 14
Study 32859250 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral medication
Number of subjects: 0
Study 32859250 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment plan
Number of subjects: 0
Study 34376972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.0 mg/kg bolus, 1.0 mg/kg/h until end of surgery)
Number of subjects: 60
Study 34376972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 60
Study 34376972 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 35085391 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 2777768
Study 35085391 — intervention group
Group type: COMPARATOR
Intervention: No positive tests (control)
Number of subjects: 2777768
Study 34517296 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with thrombolysis
Number of subjects: 379
Study 34517296 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control)
Number of subjects: 379
Study 34517296 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (comparison of outcomes)
Number of subjects: 379
Study 34686461 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 75
Study 34686461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 33734989 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 50
Study 33734989 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study 36299194 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (experimental group)
Number of subjects: 24
Study 36299194 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (control group)
Number of subjects: 24
Study 35024850 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school programme delivered by teachers and parents for 50 minutes per week
Number of subjects: 196
Study 35024850 — intervention group
Group type: COMPARATOR
Intervention: Control group (no after-school programme)
Number of subjects: 196
Study 34469858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Diffusion of Oxygen (CDO) dressing (TransCu O2, EO2 Concepts Inc., TX, USA) for 4 weeks
Number of subjects: 21
Study 34469858 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing for 4 weeks
Number of subjects: 21
Study 34469858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Diffusion of Oxygen (CDO) dressing (TransCu O2, EO2 Concepts Inc., TX, USA) for 4 weeks (thyroidectomy subgroup)
Number of subjects: 21
Study 616927963 — intervention group
Group type: COMPARATOR
Intervention: Evening testing (17:00-18:30 h)
Number of subjects: 15
Study 616927963 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (7:00-8:30 h)
Number of subjects: 15
Study 36005919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Cupping Therapy (DCT)
Number of subjects: 12
Study 36005919 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation (CS)
Number of subjects: 12
Study 36005919 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation + Dry Cupping Therapy (CS+DCT)
Number of subjects: 12
Study 36005919 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 34734875 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical monitoring through the integrated care program DiabCare Tirol
Number of subjects: 27
Study 34734875 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (from RCTs)
Number of subjects: 27
Study 32503390 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + photoactivation of H2O2 with 940 nm diode laser
Number of subjects: 38
Study 32503390 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 940 nm diode laser
Number of subjects: 38
Study 32503390 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP)
Number of subjects: 38
Study 35027421 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocortical paired associative stimulation (ccPAS) in conjunction with conventional rehabilitation treatment, 10 interventions, 5 times a week for 2 weeks.
Number of subjects: 42
Study 35027421 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment with sham stimulation.
Number of subjects: 42
Study 35027421 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocortical paired associative stimulation (ccPAS) in conjunction with conventional rehabilitation treatment.
Number of subjects: 42
Study 33798512 — intervention group
Group type: EXPERIMENTAL
Intervention: PediBIRN 4-variable clinical decision rule (CDR) applied by intervention physicians
Number of subjects: 420
Study 33798512 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 420
Study 33798512 — intervention group
Group type: EXPERIMENTAL
Intervention: PediBIRN 4-variable clinical decision rule (CDR)
Number of subjects: 420
Study 33142485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/kg star anise
Number of subjects: 384
Study 33142485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22 g/kg essential oil
Number of subjects: 384
Study 33142485 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 384
Study 33142485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/kg leavings
Number of subjects: 384
Study 35917822 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenicum album 30C
Number of subjects: 200
Study 35917822 — intervention group
Group type: EXPERIMENTAL
Intervention: Camphora 1M
Number of subjects: 200
Study 35917822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryonia alba 30C
Number of subjects: 200
Study 35917822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 33675113 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 19
Study 33675113 — intervention group
Group type: COMPARATOR
Intervention: CBT-I
Number of subjects: 19
Study 32630933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-driving-voltage liquid crystal device (7.5Vrms driving voltage)
Number of subjects: 0
Study 32630933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-driving-voltage liquid crystal device
Number of subjects: 0
Study 34060731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® (150 mg daily in 3 doses of 50 mg)
Number of subjects: 60
Study 34060731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol®
Number of subjects: 60
Study 33575976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed Older Americans Resources and Services scale
Number of subjects: 67
Study 33575976 — intervention group
Group type: COMPARATOR
Intervention: Research assistant-assessed Older Americans Resources and Services scale
Number of subjects: 67
Study 33575976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed activities of daily living
Number of subjects: 67
Study 33575976 — intervention group
Group type: COMPARATOR
Intervention: Research assistant-assessed activities of daily living
Number of subjects: 67
Study 33575976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed instrumental activities of daily living
Number of subjects: 67
Study 33575976 — intervention group
Group type: COMPARATOR
Intervention: Research assistant-assessed instrumental activities of daily living
Number of subjects: 67
Study 34893371 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA) using an eutectic mixture of lidocaine and prilocaine (EMLA)
Number of subjects: 39
Study 34893371 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 39
Study 32656729 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (subcutaneous) 0.6 mg/day to 3.0 mg
Number of subjects: 30
Study 32656729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32656729 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (subcutaneous)
Number of subjects: 30
Study 32492609 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles published after 2000
Number of subjects: 197
Study 32492609 — intervention group
Group type: COMPARATOR
Intervention: Articles published before 2000
Number of subjects: 197
Study 32492609 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact factor (IF)
Number of subjects: 197
Study 32492609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size
Number of subjects: 197
Study 32492609 — intervention group
Group type: COMPARATOR
Intervention: Publication period
Number of subjects: 197
Study 32492609 — intervention group
Group type: COMPARATOR
Intervention: Funding
Number of subjects: 197
Study 32492609 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact factor (IF) in multivariate analysis
Number of subjects: 197
Study 32492609 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting quality and IF correlation
Number of subjects: 197
Study 35683550 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawn relative
Number of subjects: 1229
Study 35683550 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated relative
Number of subjects: 1229
Study 35683550 — intervention group
Group type: COMPARATOR
Intervention: No relatives (control group)
Number of subjects: 1229
Study 33870915 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible visitation (12 hr/d) supported by family education
Number of subjects: 863
Study 33870915 — intervention group
Group type: COMPARATOR
Intervention: Usual restricted visitation (median, 1.5 hr/d)
Number of subjects: 863
Study 33940497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental pollution from the petrochemical complex (PCF)
Number of subjects: 328
Study 34426840 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative surveillance protocols (specific protocols for patients)
Number of subjects: 35
Study 34426840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up timing
Number of subjects: 35
Study 34426840 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing surveillance intensity
Number of subjects: 35
Study 34426840 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in monitoring practices
Number of subjects: 35
Study 34426840 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for further research
Number of subjects: 35
Study 33866584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 (patients alive on discharge from ICU)
Number of subjects: 1373
Study 33866584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (patients discharged alive from hospital to home)
Number of subjects: 1373
Study 32575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan extract (50 mg/day secoisolariciresinol diglucoside)
Number of subjects: 46
Study 32575611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 32575611 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Flaxseed lignan and Placebo)
Number of subjects: 46
Study 35502668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine injection
Number of subjects: 0
Study 35502668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35502668 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 32753258 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet about MRI (n = 95)
Number of subjects: 197
Study 32753258 — intervention group
Group type: COMPARATOR
Intervention: Placebo booklet (n = 102)
Number of subjects: 197
Study 36056703 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Oil (OO)
Number of subjects: 41
Study 36056703 — intervention group
Group type: COMPARATOR
Intervention: Cottonseed Oil (CSO)
Number of subjects: 41
Study 33831552 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice a day plus glargine
Number of subjects: 200
Study 33831552 — intervention group
Group type: COMPARATOR
Intervention: Aspart 70/30 twice a day
Number of subjects: 200
Study 34114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Superconducting five-qutrit processor
Number of subjects: 5
Study 34114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle benchmarking on a two-qutrit CSUM gate
Number of subjects: 5
Study 33734770 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrating positive memories
Number of subjects: 65
Study 33734770 — intervention group
Group type: COMPARATOR
Intervention: Writing positive memories
Number of subjects: 65
Study 33734770 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 65
Study 34861492 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis (LCA)
Number of subjects: 0
Study 34861492 — intervention group
Group type: EXPERIMENTAL
Intervention: X-learner with Random Forest (XL-RF)
Number of subjects: 0
Study 34861492 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal Forest (CF)
Number of subjects: 0
Study 34861492 — intervention group
Group type: EXPERIMENTAL
Intervention: Other algorithms (K-means, partition around medoids, hierarchical, spectral clustering, model-based recursive partitioning)
Number of subjects: 0
Study 34861492 — intervention group
Group type: EXPERIMENTAL
Intervention: All algorithms (except LCA)
Number of subjects: 0
Study 34861492 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing research biomarkers as partitioning variables
Number of subjects: 0
Study 32242395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liangxue Jiedu decoction (LJD)
Number of subjects: 238